Switch theme
Sign up to access all valuation multiples
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
1990
229
LTM Revenue $127M
Last FY EBITDA -$155M
$693M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Geron has a last 12-month revenue (LTM) of $127M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Geron achieved revenue of $77.0M and an EBITDA of -$155M.
Geron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Geron valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $127M | XXX | $77.0M | XXX | XXX | XXX |
| Gross Profit | $121M | XXX | $75.7M | XXX | XXX | XXX |
| Gross Margin | 95% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$155M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -201% | XXX | XXX | XXX |
| EBIT | -$132M | XXX | -$174M | XXX | XXX | XXX |
| EBIT Margin | -104% | XXX | -226% | XXX | XXX | XXX |
| Net Profit | -$136M | XXX | -$175M | XXX | XXX | XXX |
| Net Margin | -107% | XXX | -227% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $39.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Geron's stock price is $2.
Geron has current market cap of $968M, and EV of $693M.
See Geron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $693M | $968M | XXX | XXX | XXX | XXX | $-0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Geron has market cap of $968M and EV of $693M.
Geron's trades at 9.0x EV/Revenue multiple, and -4.5x EV/EBITDA.
Equity research analysts estimate Geron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Geron has a P/E ratio of -7.1x.
See valuation multiples for Geron and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $968M | XXX | $968M | XXX | XXX | XXX |
| EV (current) | $693M | XXX | $693M | XXX | XXX | XXX |
| EV/Revenue | 5.4x | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.5x | XXX | XXX | XXX |
| EV/EBIT | -5.2x | XXX | -4.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.1x | XXX | -5.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGeron's last 12 month revenue growth is 93%
Geron's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.1M for the same period.
Geron's rule of 40 is -73654% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Geron's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Geron and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 93% | XXX | 102% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -201% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -73654% | XXX | -108% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 135% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 324% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Geron acquired XXX companies to date.
Last acquisition by Geron was XXXXXXXX, XXXXX XXXXX XXXXXX . Geron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Geron founded? | Geron was founded in 1990. |
| Where is Geron headquartered? | Geron is headquartered in United States of America. |
| How many employees does Geron have? | As of today, Geron has 229 employees. |
| Who is the CEO of Geron? | Geron's CEO is Ms. Dawn Carter Bir. |
| Is Geron publicy listed? | Yes, Geron is a public company listed on NAS. |
| What is the stock symbol of Geron? | Geron trades under GERN ticker. |
| When did Geron go public? | Geron went public in 1996. |
| Who are competitors of Geron? | Similar companies to Geron include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Geron? | Geron's current market cap is $968M |
| What is the current revenue of Geron? | Geron's last 12 months revenue is $127M. |
| What is the current revenue growth of Geron? | Geron revenue growth (NTM/LTM) is 93%. |
| What is the current EV/Revenue multiple of Geron? | Current revenue multiple of Geron is 5.4x. |
| Is Geron profitable? | Yes, Geron is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
